Edgar Filing: ABIOMED INC - Form 4

| ABIOMED IN Form 4 May 17, 2017 | ïC | | | | | | | | | | | |
|--|---------------------------------------|--|----------|--|--|-----------------------|--------------|--|---|---|--|--|
| FORM | 4 | | | | | | NGEG | | OMB AF | PROVAL | | |
| - | UNITED | STATES S | | ATIES A hington, | | | ANGE C | OMMISSION | OMB Number: | 3235-0287 | | |
| Check this b if no longer subject to Section 16. Form 4 or | STATEM | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP SECURITIES | | | | | | | | Expires:January 31, 2005Estimated average burden hours per response0.5 | | |
| Form 5 obligations may continu <i>See</i> Instruct 1(b). | ility Hole | (a) of the Securities Exchange Act of 1934, ity Holding Company Act of 1935 or Section estment Company Act of 1940 | | | | | | | | | | |
| (Print or Type Res | sponses) | | | | | | | | | | | |
| BOLT WILLIAM J Symbol | | | | er Name and Ticker or Trading MED INC [ABMD] | | | | 5. Relationship of Reporting Person(s) to Issuer | | | | |
| | | | | of Earliest Transaction | | | | (Check all applicable) | | | | |
| | | | | n/Day/Year) /2017 | | | | Director 10% Owner X Officer (give title Other (specify below) below) SVP, QA and Regulatory Affairs | | | | |
| DANK/EDG A | (Street) | | | ndment, Da th/Day/Year | - | l | | 6. Individual or Joi Applicable Line) _X_ Form filed by O Form filed by M | ne Reporting Per | son | | |
| DANVERS, MA 01923 Form filed by More than One Reporting Person | | | | | | | | | | | | |
| (City) | (State) | (Zip) | Table | e I - Non-E | Derivative | Secu | rities Acqu | iired, Disposed of, | or Beneficiall | y Owned | | |
| | . Transaction Date Month/Day/Year) | 2A. Deemed Execution I any (Month/Day | Date, if | 3. Transactic Code (Instr. 8) | 4. Securi on(A) or Di (Instr. 3, | spose 4 and (A) | d of (D) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | | Code V | Amount | or (D) | Price | (Instr. 3 and 4) | | | | |
| Common Stock, \$.01 0 par | 5/15/2017 | | | F <u>(5)</u> | 4,473 (5) | D | \$ 131.42 | 56,003 | D | | | |
| Common Stock, \$.01 0 par | 5/15/2017 | | | A <u>(6)</u> | 8,198 (<u>6)</u> | А | \$ 0 | 64,201 | D | | | |
| Common Stock, \$.01 0 par | 05/15/2017 | | | A <u>(7)</u> | 2,000 (7) | A | \$ 0 | 66,201 | D | | | |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transactio Code (Instr. 8) | 5. Number on f Deriva Securities Acquired (A) or Disposed (D) (Instr. 3, 4 and 5) | tive s | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | |
|---|---|---|---|--|---|-----------|--|--------------------|---|--|
| | | | | Code V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Option (Right to Buy) (2) | \$ 23.15 | | | | | | 05/14/2014(1) | 05/14/2023 | Common stock | 0 |
| Stock Option (Right to Buy) (2) | \$ 21.55 | | | | | | 05/14/2015 <u>(3)</u> | 05/14/2024 | Common Stock | 0 |
| Stock Option (Right to Buy) (2) | \$ 66.25 | | | | | | 05/13/2016 <u>(3)</u> | 05/13/2025 | Common Stock | 0 |
| Stock Option (Right to Buy) (4) | \$ 99.62 | | | | | | 05/24/2017 <u>(3)</u> | 05/24/2026 | Common Stock | 0 |
| Stock Option (Right to Buy) (4) | \$ 134.51 | 05/15/2017 | | A | 3,000 | | 05/15/2018 <u>(3)</u> | 05/15/2027 | Common Stock | 3,000 |
| Reporting Owners | | | | | | | | | | |
| | | | | D L d | | | | | | |

| Reporting Owner Name / Address | Relationships | | | | | | |
|--------------------------------|---------------|-----------|--------------------------------|-------|--|--|--|
| 1 8 | Director | 10% Owner | Officer | Other | | | |
| | | | SVP, QA and Regulatory Affairs | | | | |

BOLT WILLIAM J C/O ABIOMED, INC. 22 CHERRY HILL DRIVE DANVERS, MA 01923

Signatures

/s/ Stephen C. McEvoy (by power of attorney)

05/17/2017

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These options become exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6.
- (2) Grant to reporting person of this option to buy the number of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan.
- (3) These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.
- (4) Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan.
- (5) Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with vesting of awards of restricted stock units.

Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on May 24, 2016. One third of these restricted stock units will vest on May 24, 2017 (into an equal number of shares of common stock)

(6) based on the issuer's achievement of a certain performance milestone and upon the first anniversary of the date of the grant with the remaining vesting on the second and third anniversaries of the date of grant as long as the reporting person continues to be employed by the issuer on the vesting dates.

Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares(7) will be issued to the reporting person on each of May 15, 2018, May 15, 2019 and May 15, 2020, so long as the reporting person continues to be employed by the issuer on the vesting dates.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.